CD28 and Alzheimer disease: Our observations employing a technique making possible to distinguish (virtually “see” in the FACS plots) and quantify single dividing lymphocytes seem to support the ability of CD4+CD28+ cells of AD patients to specifically proliferatively respond to Aβ peptide, but at a level not exceeding that seen for other antigens.